CytoDyn

CYDY · OTCQB · United States

Share price · CYDY

$0.20-0.15 (-42.86%) 3M

no price since 18 Aug 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CYDY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 13 Aug 2026+5.3%
  2. 23 Apr 2026-11.8%
  3. 16 Apr 2026+8.8%

    Nothing announced by CYDY that day or the session before.

  4. 13 Apr 2026+13.8%

    Nothing announced by CYDY that day or the session before.

  5. 26 Mar 2026+11.5%
  6. 16 Mar 2026+11.5%

    Nothing announced by CYDY that day or the session before.

  7. 26 Feb 2026-7.7%
  8. 19 Feb 2026+8.0%

    Nothing announced by CYDY that day or the session before.

  9. 17 Nov 2025+14.8%
  10. 3 Nov 2025+8.3%

Share of unusual movement by asset

For each asset, the share of CYDY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Leronlimab
events and moves
133%
Other company news (earnings, financing, releases naming no asset)—14%
Sessions with no dated event—84%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2/3
CCR5 co-receptorMonoclonal antibody
Alzheimer's DiseaseHIVColorectal Cancer
Metastatic Colorectal Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
January 2028 (1)
LeronlimabPhase 2Metastatic Colorectal Cancer (mCRC)
Est. primary completion 2028-01 · NCT06699836 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3——$16M$20M-$7.7M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1——$16M$4.7M-$5.5M operating cash flowreport ↗
2025-Q4——$5.0M$23M-$4.3M operating cash flowreport ↗
2025-Q3——$9.3M$5.5M-$2.5M operating cash flowreport ↗
2025-Q1——$16M$4.8M-$5.0M operating cash flowreport ↗
2024-Q4——$21M$4.8M-$3.6M operating cash flowreport ↗
2024-Q3——$25M—$5.4M operating cash flowreport ↗
2024-Q1—$0.7M$8.0M$12M-$2.3M operating cash flowreport ↗
2023-Q4—$1.1M$6.7M$9.6M-$2.5M operating cash flowreport ↗
2023-Q3—$1.9M$8.6M$12M-$4.5M operating cash flowreport ↗
2023-Q1—$0.9M$11M$14M-$6.2M operating cash flowreport ↗
2022-Q4—$0.1M$2.6M$27M-$4.4M operating cash flowreport ↗
2022-Q3—$0.6M$4.7M$21M-$11M operating cash flowreport ↗
2022-Q1—$9.1M$2.4M$32M-$11M operating cash flowreport ↗
2021-Q4$0.2M$9.0M$8.9M$37M-$29M operating cash flowreport ↗
2021-Q3<$0.1M$14M$6.5M$31M-$32M operating cash flowreport ↗

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY——$12M$11M-$17M operating cash flowreport ↗
View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY——$12M—-$8.8M operating cash flowreport ↗
2024-FY—$7.2M$9.8M$12M-$11M operating cash flowreport ↗
2023-FY$0$2.6M$9.1M$20M-$25M operating cash flowreport ↗
2022-FY$0.3M$27M$4.2M$53M-$78M operating cash flowreport ↗
2021-FY$0$58M$34M$39M-$118M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-20Hoffman Robert E. · Chief Executive OfficerAward / grant (derivative)2,500,000——Form 4
2026-03-20Blok Tyler · Chief Legal OfficerAward / grant (derivative)3,249,794——Form 4
2026-03-20Brunke Karen J · directorAward / grant (derivative)574,385——Form 4
2026-03-20Dunlap Ryan · directorAward / grant (derivative)574,385——Form 4
2026-03-20Hoffman Robert E. · Chief Financial OfficerAward / grant (derivative)4,874,691——Form 4
2026-03-20Lalezari Jacob P · Chief Executive OfficerAward / grant (derivative)4,874,691——Form 4
2026-03-20Ndhlovu Lishomwa C · directorAward / grant (derivative)574,385——Form 4
2026-03-20SIMES STEPHEN M · directorAward / grant (derivative)574,385——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 8 reporting institutions held 0.3M shares ($84K, 0.0% of shares outstanding).

#InstitutionSharesValue
1NBC SECURITIES, INC.160,000$44K
2Diversified Trust Co45,790$13K
3Williams Jones Wealth Management, LLC.45,001$12K
4Next Capital Management LLC25,000$7K
5HORIZON FINANCIAL SERVICES, LLC18,200$5K
6Ancora Advisors LLC9,488$3K
7CAZ INVESTMENTS LP4,000$1K
8VSM Wealth Advisory, LLC500$137